MiMedx Group (NASDAQ:MDXG) Stock Rating Reaffirmed as “Overweight” by Cantor Fitzgerald

MiMedx Group (NASDAQ:MDXG – Get Free Report)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a note issued to investors on Tuesday, Benzinga reports. They presently have a $8.00 price objective on the stock. Cantor Fitzgerald‘s price objective would suggest a potential upside of 151.57% from the stock’s previous close.

Other analysts have also issued research reports about the stock. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, October 29th. Seaport Research Partners lowered shares of MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Wall Street Zen upgraded shares of MiMedx Group from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Mizuho set a $7.00 target price on shares of MiMedx Group in a research report on Thursday, October 29th. Finally, Craig Hallum boosted their target price on shares of MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, MiMedx Group has a consensus rating of “Moderate Buy” and an average target price of $8.14.

Read Our Latest Report on MDXG

MiMedx Group Stock Performance

Shares of MiMedx Group stock opened at $3.18 on Tuesday. MiMedx Group has a 52 week low of $3.03 and a 52 week high of $7.51. The stock has a 50 day moving average price of $4.23 and a two-hundred day moving average price of $4.17. The stock has a market capitalization of $464.06 million, a PE ratio of -24.46 and a beta of 1.17.

MiMedx Group (NASDAQ:MDXG – Get Free Report) last issued its earnings results on Wednesday, October 28th. The company reported ($0.01) earnings per share for the quarter. MiMedx Group had a positive return on equity of 2.39% and a negative net margin of 6.32%. The firm had revenue of $62.28 million for the quarter, compared to analyst estimates of $68.56 million. Research analysts forecast that MiMedx Group will post -0.08 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Punch & Associates Investment Management Inc. bought a new stake in MiMedx Group during the second quarter worth $7,924,000. Squarepoint Ops LLC raised its position in MiMedx Group by 73.7% in the 2nd quarter. Squarepoint Ops LLC now owns 571,930 shares of the company’s stock valued at $2,202,000 after buying an additional 242,714 shares during the last quarter. Paradigm Capital Management Inc. NY purchased a new stake in MiMedx Group in the 2nd quarter valued at $15,681,000. Nantahala Capital Management LLC bought a new position in MiMedx Group during the 2nd quarter valued at $18,355,075. Finally, Bank of New York Mellon Corp bought a new position in MiMedx Group during the 2nd quarter valued at $1,629,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

(Get Free Report)

MiMedx Group is a healthcare company that develops and markets biologic products made from donated human placental tissue. Its offerings include amniotic membrane and umbilical cord allografts for use in wound care and surgical procedures. The company’s products include EpiFix, used in the management of certain chronic wounds, and other tissue-based products for wound and surgical applications. MiMedx uses its proprietary PURION processing method to prepare donated tissue for clinical use. Founded in 2008 and headquartered in Marietta, Georgia, MiMedx primarily serves healthcare providers in the United States, with sales in select international markets.

Recommended Stories

Analyst Recommendations for MiMedx Group (NASDAQ:MDXG)

Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.